Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design

AAPS Journal

Volumn 18, Issue 3, 2016, Pages 635-646

  Maass, Katie F ^a,b   Kulkarni, Chethana ^c   Betts, Alison M ^c   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c PFIZER INC   (United States)

Author keywords

Antibody drug conjugate; Cellular trafficking; Pharmacokinetics pharmacodynamics; T DM1; Trastuzumab emtansine

Indexed keywords

ANTIBODY DRUG CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE; TRASTUZUMAB MAYTANSINOID ANTIBODY DRUG CONJUGATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIGEN BINDING; ARTICLE; CELL GROWTH; DRUG DEGRADATION; DRUG DESIGN; DRUG HALF LIFE; EFFLUX RATE; ENDOCYTOSIS; FLOW CYTOMETRY; FLUORESCENCE IMAGING; GROWTH RATE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INTERNALIZATION; INTERNALIZATION RATE; KINETICS; PHARMACOLOGICAL PARAMETERS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; CELL MEMBRANE; CHEMISTRY; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MEMBRANE; DRUG DESIGN; HUMANS; MAYTANSINE; TRASTUZUMAB;

EID: 85007524193     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9892-3     Document Type: Article

References (48)

1. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov [Internet]. 2013;12(4):259-60. Available from: http://www.nature.com/doifinder/10.1038/nrd3980.
2. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34-45.
3. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18536555.
4. McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J [Internet]. 2015;(6). Available from: http://link.springer.com/10.1208/s12248-014-9710-8
5. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res [Internet]. 2004 Oct 15 [cited 2012 Mar 31];10(20):7063-70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15501986.
6. Kovtun Y V, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett [Internet]. 2007 Oct 8 [cited 2012 Apr 26];255(2):232-40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17553616.
7. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res [Internet]. 2014 Jan [cited 2014 Oct 9];16(2): 209. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4058749 &tool=pmcentrez&rendertype=abstract
8. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn [Internet]. 2012 Dec [cited 2012 Dec 10];39(6):643-59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23151991.
9. Shah DK, King LE, Han X, Wentland J-A, Zhang Y, Lucas J, et al. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5t4 antibody-drug conjugate. AAPS J [Internet]. 2014 Mar 1 [cited 2014 Apr 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24578215.
10. Sukumaran S, Gadkar K, Zhang C, Bhakta S, Liu L, Xu K, et al. Mechanism-based pharmacokinetic/pharmacodynamic model for THIOMABTM drug conjugates. Pharm Res [Internet]. 2014;1884-93. Available from: http://link.springer.com/10.1007/s11095-014-1582-1
11. Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res [Internet]. 2015;32(11):3508-25. Available from: http://link.springer.com/10.1007/s11095-015-1626-1
12. Sadekar S, Figueroa I, Tabrizi M. Antibody drug conjugates: application of quantitative pharmacology in modality design and target selection. AAPS J [Internet]. 2015;17(4):828-36. Available from: http://link.springer.com/10.1208/s12248-015-9766-0
13. Burris H a, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer [Internet]. 2011 Oct [cited 2012 Jul 15];11(5):275-82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21729661.
14. Wada R, Erickson HK, Lewis Phillips GD, Provenzano C a, Leipold DD, Mai E, et al. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol [Internet]. 2014 Nov 4 [cited 2014 Oct 1];74(5):969-80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25186956.
15. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano C a, Mai E, Johnson H a, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther [Inter-net]. 2012 May [cited 2012 Aug 6];11(5):1133-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22408268.
16. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn [Internet]. 2010 Jun [cited 2014 Jan 12];37(3):221-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20424896.
17. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther [Internet]. 2012;92(4):520-7. Available from: http://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=3745717&tool=pmcentrez &rendertype=abstract
18. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52(8):657-72
19. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229-40.
20. Maass KF, Kulkarni C, Quadir MA, Hammond PT, Betts AM, Wittrup KD. A flow cytometric clonogenic assay reveals the single-cell potency of doxorubicin. J Pharm Sci [Internet]. 2015 Sep;n/a -n/a. Available from: http://doi.wiley.com/10.1002/jps.24631.
21. Chari RVJ, Martell BA, Gross JL, Gross L, McKenzie SJ, Goldmacher VS, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 1992;52(1):127-31.
22. Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther [Internet]. 2015;14(April):952-64. Available from: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-14-0862
23. Linderman J, Lauffenburger D. Receptors: models for binding, trafficking, and signaling. Oxford: Oxford University Press; 1993.
24. Lund KA, Opresko LK, Starbuck C, Walsh BJ, Wiley HS. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J Biol Chem. 1990.
25. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother [Internet]. 2008 Dec [cited 2011 Jun 29];57(12):1879-90. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2840397&tool=pmcentrez&rendertype=abstract.
26. Harper J, Mao S, Strout P, Kamal A. Selecting and optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. In: Ducry L, editor. Methods in Molecular Biology [Internet]. Totowa, NJ: Humana Press; 2013 [cited 2014 Apr 1]. p. 41-9. Available from: http://link.springer.com/10.1007/978-1-62703-541-5.
27. Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther [Internet]. 2010 Oct [cited 2014 Apr 1];9(10):2689-99. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2954514 &tool=pmcentrez&rendertype=abstract
28. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin a-M, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif [Internet]. 2007 Aug;40(4):580-94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17635524.
29. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther [Internet]. 2013 Sep [cited 2014 Jan 12];12(9):1816-28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23723124.
30. Pillow TH, Tien J, Parsons-reponte KL, Bhakta S, Li H, Staben LR, et al. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. 2014.
31. Austin CD, Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15:5268-82.
32. Erickson HK, Park PU, Widdison WC, Kovtun Y V, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res [Internet]. 2006 Apr 15 [cited 2012 Mar 30];66(8):4426-33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16618769.
33. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res [Internet]. 2008 Nov 15 [cited 2014 Jan 10];68(22):9280-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19010901.
34. Rodríguez A, Webster P, Ortego J, Andrews NW. Lysosomes behave as Ca2 + -regulated exocytic vesicles in fibroblasts and epithelial cells. J Cell Biol. 1997;137(1):93-104.
35. Safaei R, Larson BJ, Cheng TC, Gibson M a, Otani S, Naerdemann W, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005;4(10):1595-604
36. Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014;9(2).
37. Brinton LT, Sloane HS, Kester M, Kelly KA. Formation and role of exosomes in cancer. Cell Mol Life Sci [Internet]. 2014;72(4):659-71. Available from: http://link.springer.com/10.1007/s00018-014-1764-3.
38. Cilliers C, Liao J, Atangcho L, Thurber GM. Residualization rates of near-infrared dyes for the rational design of molecular imaging agents. Mol Imaging Biol [Internet]. 2015; Available from: http://link.springer.com/10.1007/s11307-015-0851-7
39. Singh R, Salomon PL. A sensitive ELISA method for the measurement of catabolites of antibody-drug conjugates (ADCs) in target cancer cells. Mol Pharm [Internet]. 2015;150304113735005. Available from: http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00028
40. Spiegelman BM, Lopata M a, Kirschner MW. Multiple sites for the initiation of microtubule assembly in mammalian cells. Cell. 1979;16(2):239-52
41. Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015.
42. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev [Internet]. 2008 Sep [cited 2014 Dec 11];60(12):1421-34. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2820307 &tool=pmcentrez&rendertype=abstract
43. Thurber GM, Dane Wittrup K. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol [Internet]. Elsevier; 2012 Dec 7 [cited 2012 Dec 3];314:57-68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22974563.
44. Perrino E, Steiner M, Krall N, Bernardes GJL, Pretto F, Casi G, et al. Curative properties of non-internalizing antibody-drug conjugates based on maytansinoids. Cancer Res [Internet]. 2014 Feb 11 [cited 2014 Apr 1]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24520075
45. Casi G, Neri D. Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm [Internet]. 2015;12(6):1880-4. Available from: http://pubs.acs.org/doi/abs/10.1021/mp500798y.
46. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res [Internet]. 2010 Feb 1 [cited 2014 Mar 28];16(3):888-97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20086002.
47. Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK, et al. SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res [Internet]. 2015;75(24):5329-40. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-15-1610.
48. Rock BM, Tometsko ME, Patel SK, Hamblett KJ, Fanslow WC, Rock DA. Intracellular catabolism of an antibody drug conjugate with a noncleavable linker. Drug Metab Dispos [Internet]. 2015;43(9):1341-4. Available from: http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.115.064253.